Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22883638 | 0.89 | PIK3CD (0.44) | GSK3AGSK3BPIK3CDJAK2ROCK2 | |
| SCHEMBL22883563 | 0.88 | JAK2 (0.45) | GSK3AGSK3BPIK3CDJAK2ROCK2 | |
| SCHEMBL19320381 | 0.88 | JAK2 (0.45) | GSK3AGSK3BPIK3CDJAK2ROCK2 | |
| SCHEMBL19325087 | 0.85 | GSK3A (0.46) | GSK3AGSK3BPIK3CDJAK2ROCK2 | |
| SCHEMBL18052124 | 0.85 | GSK3A (0.53) | GSK3AGSK3BPIK3CDJAK2ROCK2 | |
| SCHEMBL27851301 | 0.84 | GSK3A (0.64) | GSK3AGSK3BPIK3CDJAK2ROCK2 | |
| SCHEMBL10304368 | 0.84 | GSK3A (0.64) | GSK3AGSK3BPIK3CDJAK2ROCK2 | |
| SCHEMBL10304636 | 0.83 | CDC7 (0.59) | GSK3AGSK3BJAK2ROCK2PRKACA | |
| SCHEMBL19320375 | 0.83 | GSK3A (0.45) | GSK3AGSK3BJAK2SRCFLT3 | |
| SCHEMBL19325153 | 0.83 | GSK3A (0.45) | GSK3AGSK3BJAK2SRCFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191489-B1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-01-06 | — | — | EP | disclosed |
| US-9932346-B2 | Pyrrolopyrimidines for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-03 | — | — | US | disclosed |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | IMPDH1, IMPDH2, TYMP | KMT2A 2122/4885GSK3A 2643/4885GSK3B 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.